Pharmacology: MRONJ risk factor
نویسندگان
چکیده
منابع مشابه
Clinical Pharmacology and Vascular Risk
Pharmacological treatment and several drugs of abuse have been associated with ischemic heart disease (IHD) and cerebrovascular diseases (CVD). However, there is a paucity of data on the independent risk of vascular disease (VD) associated with pharmacological treatment and no controlled trials demonstrating a reduction in risk with abstinence. Information about IHD and CVD-related drug abuse i...
متن کاملMetabolic Syndrome as a Risk Factor for Osteoarthritis
Metabolic syndrome refers to a set of conditions that include high blood pressure, increased insulin level in the blood, the accumulation of the excess fat around the abdomen, and increased blood lipids. In metabolic syndrome, the vast majority of these conditions are simultaneously present, and the risk of developing heart disease, stroke, and diabetes rises. Besides, osteoarthritis or degen...
متن کامل[Differences in pharmacology of tumor necrosis factor (TNF) antagonists].
The commercially available inhibitors of TNF are constituted by two classes of molecules: the soluble receptors (Etanercept: Amgen Inc. Wyeth) and the monoclonal antibodies (Adalimumab: Abbott Laboratories and Infliximab: Centocor, Inc.). The differences in their molecular structure, mechanism of action, pharmacokinetics (PK) and pharmacodynamics (PD) are discussed, along with the differences c...
متن کاملFibroblast growth factor 21: from pharmacology to physiology.
Fibroblast growth factor 21 (FGF21) is an atypical member of the FGF family that functions as an endocrine hormone. Pharmacologic studies show that FGF21 has broad metabolic actions in obese rodents and primates that include enhancing insulin sensitivity, decreasing triglyceride concentrations, and causing weight loss. In lean rodents, FGF21 expression is strongly induced in liver by prolonged ...
متن کاملAnesthetic Pharmacology Preclinical Pharmacology
Daniel I. Sessler, MD† BACKGROUND: In previous studies, we showed that failure to respond to automated responsiveness monitor (ARM) precedes potentially serious sedationrelated adversities associated with loss of responsiveness, and that the ARM was not susceptible to false-positive responses. It remains unknown, however, whether loss and return of response to the ARM occur at similar sedation ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Dental Journal
سال: 2018
ISSN: 0007-0610,1476-5373
DOI: 10.1038/sj.bdj.2018.132